Corporate Profile
We are a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of metabolic dysfunction-associated steatohepatitis (MASH), chronic hepatitis B (CHB) and coronavirus.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Events
Jul 18, 2024 at 3:00 PM EDT
Mar 7, 2024 at 4:00 PM EST